Evolent Health (EVH) General Counsel receives RSU grant with tax-withholding entry
Evolent Health's General Counsel, Jonathan Weinberg, received a grant of 43,055 restricted stock units (RSUs) on July 1, 2026, as part of his annual equity compensation. Concurrently, 2,650 shares were withheld to cover tax obligations upon the vesting of previously granted RSUs, which is a non-market disposition. Following these transactions, Weinberg directly holds 287,567 shares of Class A Common Stock, with the new RSUs vesting over three years.
Evolent Health (EVH) CEO gets 446,102 RSUs and has shares withheld for taxes
Evolent Health, Inc.'s CEO, Seth Blackley, was granted 446,102 restricted stock units (RSUs) with a vesting schedule extending to 2029. To cover tax obligations upon the vesting of these RSUs, 10,297 shares of Class A Common Stock, valued at $5.74 per share, were withheld. Following these transactions, Blackley directly holds 1,283,064 shares of Class A Common Stock.
Evolent Health (EVH) grants 28,790 RSUs to Chief Accounting Officer
Evolent Health, Inc. (EVH) has granted 28,790 restricted stock units (RSUs) to its Chief Accounting Officer, Shams Aammaad, under the company's 2015 Omnibus Incentive Compensation Plan. These RSUs will vest in tranches: 34% on July 1, 2027, and 33% on both July 1, 2028, and July 1, 2029. This grant increases Mr. Aammaad's total reported holdings, including prior RSU awards, to 95,637 shares.
Enterprise value to EBIT forward of Evolent Health Inc Class A – FWB:9EH
This page provides financial data for Evolent Health Inc Class A (FWB:9EH) on the Frankfurt Stock Exchange, specifically focusing on its enterprise value to EBIT forward. It indicates that the market is currently closed with no trades recorded. The data is presented within the TradingView platform, which also offers various other financial tools and community features.
Price to sales forward of Evolent Health Inc Class A – FWB:9EH
This article provides the "Price to sales forward" metric for Evolent Health Inc Class A (FWB:9EH) on the Frankfurt Stock Exchange. It appears to be a financial data point from TradingView, indicating a specific valuation ratio for the company over a given period, along with its change in value and percentage. The content is primarily a data presentation with surrounding navigation and copyright information.
Evolent Health Inc Class A Actuals & Estimates (NYSE:EVH)
This article provides an overview of Evolent Health, Inc. (EVH) stock, including current market data, analyst forecasts, and detailed financial information. It covers the stock's price performance, market capitalization, earnings, revenue, and EBITDA, along with frequently asked questions about investing in the company.
Analysts Offer Insights on Healthcare Companies: Amneal Pharmaceuticals (AMRX), Evolent Health (EVH) and Celldex (CLDX)
This article highlights bullish sentiments from financial analysts on three healthcare companies: Amneal Pharmaceuticals (AMRX), Evolent Health (EVH), and Celldex (CLDX). UBS reiterated a Buy rating for Amneal Pharmaceuticals, while Truist Financial maintained a Buy rating for Evolent Health. Morgan Stanley also reconfirmed a Buy rating for Celldex, noting a significant upside potential.
Evolent Health (EVH) director Russell Glass receives 41,096 restricted stock units
Evolent Health, Inc. director Russell Monroe Glass was granted 41,096 restricted stock units (RSUs) of Class A Common Stock at $0.00 per share under the company’s 2015 Omnibus Incentive Compensation Plan. These RSUs are set to vest on the earlier of June 4, 2027, or the company's 2027 annual meeting, contingent on his continued service. Following this award, Glass directly holds 77,347 shares and indirectly holds 6,046 shares through a trust.
Director at Evolent Health (EVH) receives 41,096-share RSU grant
Evolent Health director Brendan B. Springstubb was granted 41,096 restricted stock units (RSUs) of Class A Common Stock, valued at $0.00 per share, under the company's 2015 Omnibus Incentive Compensation Plan. Following this grant, his direct holdings total 99,917 shares. These RSUs will vest by June 4, 2027, or the company's 2027 annual meeting, dependent on his continued service.
Evolent Health (EVH) director receives 41,096 restricted stock units grant
Evolent Health, Inc. director Peter J. Grua was granted 41,096 restricted stock units (RSUs) of Class A Common Stock at $0.00 per share, as reported in a Form 4 filing. These RSUs are compensation-related and will vest on the earlier of June 4, 2027, or the company's 2027 annual meeting, contingent on his continued service. Following this grant, Grua directly holds 63,075 shares and indirectly holds an additional 60,668 shares through a revocable trust.
Evolent Health (EVH) director Kim Keck granted 41,096 restricted stock units
Evolent Health director Kim Keck was granted 41,096 restricted stock units (RSUs) under the company's 2015 Omnibus Incentive Compensation Plan, increasing her direct ownership to 102,597 shares. These RSUs will vest on the earlier of June 4, 2027, or the company’s 2027 annual meeting, contingent on her continued board service. The grant was reported in a Form 4 filing and is considered a neutral event for the company's stock.
Equity grant lifts Evolent (NYSE: EVH) director Barbarosh holdings
Evolent Health director Craig A. Barbarosh was granted 41,096 restricted stock units (RSUs) as part of the company's 2015 Omnibus Incentive Compensation Plan, at no cash cost. These RSUs are set to vest by June 4, 2027, or the company's 2027 annual meeting, contingent on his continued board service. Following this grant, Barbarosh directly holds 95,031 shares of Class A Common Stock.
Evolent Health (EVH) director receives 41,096 restricted stock units award
Jill D. Smith, a director at Evolent Health (EVH), was granted 41,096 restricted stock units (RSUs) as equity compensation, increasing her total direct holdings to 64,233 shares. These RSUs, part of the 2015 Omnibus Incentive Compensation Plan, will vest on the earlier of June 4, 2027, or the company's 2027 annual meeting, contingent on her continued service. The transaction was reported as a grant rather than a market purchase, with a reported price of $0.00 per share.
[Form 4] Evolent Health, Inc. Insider Trading Activity
Evolent Health, Inc. director Shawn M. Guertin reported receiving an equity award of 41,096 restricted stock units of Class A Common Stock. These units were granted at no cash cost under the company's 2015 Omnibus Incentive Compensation Plan and vest on the earlier of June 4, 2027, or the 2027 annual meeting, contingent on his continued service. Following this transaction, Guertin directly holds 63,075 shares of Evolent Health Class A Common Stock.
Evolent Health (EVH) director receives 41,096 restricted stock units in equity grant
Richard M. Jelinek, a director at Evolent Health (EVH), received an equity grant of 41,096 restricted stock units (RSUs) with no purchase price. These RSUs will vest on the earlier of June 4, 2027, or the company's 2027 annual meeting, provided Jelinek continues his service. Following this grant, Jelinek directly holds 77,533 Class A common shares and indirectly holds an additional 30,000 shares through two trusts.
Evolent Health (EVH) holders back board, auditor and pay plan at 2026 meeting
Evolent Health (EVH) stockholders approved all proposals at their 2026 annual meeting, including the election of ten director nominees, the ratification of Deloitte & Touche LLP as their independent registered public accounting firm, and an advisory vote on 2025 executive compensation. Investors also approved an amendment to the 2015 Omnibus Incentive Compensation Plan. These decisions indicate strong stockholder support for the company's current governance and executive compensation frameworks.
Evolent Health : EVH
Evolent Health Inc. (EVH) specializes in healthcare management, offering services in oncology, cardiology, and musculoskeletal care, backed by its Identifi technology. The company, founded in 2011 and based in Arlington, Virginia, supports health plan administration and provides a value-based business infrastructure. Its stock data shows a current price of $3.95 with a target of $3, reflecting a 16.5% decrease.
Evolent Health : EVH
This article provides an overview of Evolent Health Inc. (EVH), a company specializing in healthcare management services, particularly in specialty care areas like oncology and cardiology. It highlights the company's focus on value-based care infrastructure and its proprietary technology, Identifi, alongside its current stock data and a recent article mentioning it in the context of AI in healthcare.
Analysts’ Top Healthcare Picks: ProMIS Neurosciences (PMN), Evolent Health (EVH)
Analysts from Maxim Group and William Blair have issued bullish sentiments on ProMIS Neurosciences (PMN) and Evolent Health (EVH) respectively. ProMIS Neurosciences received a Buy rating with a $35.00 price target, while Evolent Health also maintained a Buy rating with a consensus price target of $5.85, indicating a 43.7% upside. Both companies are highlighted for their potential in the healthcare sector.
Evolent Health, Inc. (NYSE:EVH) Just Released Its First-Quarter Earnings: Here's What Analysts Think
Evolent Health, Inc. (NYSE:EVH) recently reported first-quarter earnings, with shares surging 14%. While revenues came in below estimates, statutory losses were smaller than predicted. Analysts maintain a consensus price target of US$5.43, with expectations for significant revenue growth and reduced losses in 2026, outpacing the wider industry.
Evolent Health (EVH) Narrows Q1 Loss To US$26.6 Million Testing Bullish Margin Narratives
Evolent Health (EVH) reported a Q1 2026 net loss of US$26.6 million on US$496.2 million in revenue, narrowing its loss from the previous quarter but still operating in loss-making territory. Analysts anticipate significant long-term margin improvement and profit, heavily relying on future operational shifts not yet reflected in current financials. The company's low price-to-sales ratio contrasts with ongoing losses and high share price volatility, presenting a complex picture for investors.
Evolent Health (NYSE: EVH) trims Q1 2026 loss as revenue tops $496M
Evolent Health (NYSE: EVH) reported a narrower net loss of $26.6 million for Q1 2026, a significant improvement from the $72.3 million loss in Q1 2025, with revenue climbing to $496.2 million. The company's basic and diluted loss per share decreased to $0.24, compared to $0.63 in the prior year. This financial performance was primarily driven by growth across its Medicaid, Medicare, and commercial lines, despite certain market and regulatory changes.
Evolent (NYSE: EVH) trims Q1 2026 loss as costs rise, keeps outlook
Evolent Health, Inc. reported slightly increased Q1 2026 revenue of $496.2 million, with net loss narrowing to $26.6 million. However, adjusted EBITDA declined due to rising medical costs, reflected in a higher medical expense ratio of 93.3%. The company reaffirmed its full-year 2026 guidance and announced new revenue agreements, including a significant imaging contract and a Performance Suite expansion.
Evolent Announces First Quarter 2026 Results
Evolent Health, Inc. announced its financial results for the first quarter ended March 31, 2026, reporting revenue of $496.2 million and a net loss attributable to common shareholders of $26.6 million. Despite a net loss, the company reiterates its full-year 2026 revenue guidance of $2.4 billion to $2.6 billion and Adjusted EBITDA of $110 million to $140 million, highlighting successful oncology launches and new revenue agreements for its complex specialty care solutions. Evolent continues to focus on market leadership in oncology, exploring AI opportunities, and fulfilling commitments to stakeholders.
Evolent To Release First Quarter 2026 Financial Results on Thursday, May 7, 2026
Evolent Health, Inc. (NYSE: EVH) announced that it will release its first quarter 2026 financial results on Thursday, May 7, 2026, before market open. A conference call for shareholders and interested participants will follow at 8 a.m. ET, accessible via Evolent's investor relations website. An audio playback of the call will be available for 90 days.
[SCHEDULE 13G/A] Evolent Health, Inc. Amended Passive Investment Disclosure
The Vanguard Group filed an Amendment No. 8 to a Schedule 13G/A for Evolent Health, Inc. (EVH), reporting that its beneficial ownership is now 0 shares (0%) due to an internal realignment. This realignment, effective January 12, 2026, means certain Vanguard subsidiaries will now report their holdings disaggregated from the main group. The filing clarifies that this is an administrative reporting change and not an indicator of trading activity by Vanguard.
Evolent announces appointment of Archie Mayani as chief product officer
Evolent Health, Inc. has announced the appointment of Archie Mayani as Chief Product Officer. Mayani brings over two decades of experience in healthcare technology and AI, having previously held leadership roles at GHX, Change Healthcare, UnitedHealth Group, and Amazon. Her expertise in value-based care, health tech, and AI transformation is expected to accelerate Evolent's product strategy and enhance its offerings for complex conditions.
EVH Stock Price, Quote & Chart | EVOLENT HEALTH INC - A (NYSE:EVH)
This article provides an overview of Evolent Health Inc. (EVH) stock, including its current price of $2.99, recent performance, and key financial metrics. The company reported Q4 earnings recently, beating EPS expectations but missing revenue, and analysts forecast a significant price increase for the stock over the next year. Both technical and fundamental analysis by ChartMill indicate challenges for EVH, with low ratings for both aspects.
Evolent Health (NYSE: EVH) CEO reports PSU grant and tax-withheld share dispositions
Evolent Health, Inc. CEO Seth Blackley reported significant equity award activity, including the grant of 1,425,310 performance-based share units (PSUs) and the acquisition of 58,921 Class A Common Stock shares from prior PSU settlements. To cover tax obligations, multiple dispositions of Class A Common Stock were made with specific share prices. Following these transactions, Blackley directly holds 836,962 Class A Common Stock shares and the newly granted PSUs, which are eligible to be earned based on future stock price and service conditions.
Precision Trading with Evolent Health Inc Class A (EVH) Risk Zones
The article discusses precision trading strategies for Evolent Health Inc Class A (EVH) based on AI-generated signals. It outlines institutional trading strategies including position, momentum breakout, and risk hedging, emphasizing risk management. The analysis provides support and resistance levels for various time horizons for EVH.
Evolent Health (EVH) president awarded PSUs and withholds shares for taxes
Evolent Health president Daniel McCarthy reported receiving 826,440 performance-based share units (PSUs) and acquiring 39,281 shares of Class A common stock from a prior PSU settlement. Concurrently, he had 24,027, 18,192, and 7,811 Class A shares withheld at prices between $3.25 and $3.58 to cover tax obligations. Following these transactions, McCarthy directly owns 423,022 Class A shares.
Evolent Health (NYSE: EVH) GC logs PSU grant and tax-share withholdings
Evolent Health's General Counsel, Jonathan Weinberg, reported receiving a grant of 179,661 performance-based share units and 4,910 shares of Class A Common Stock. The filing also detailed several tax-withholding dispositions where shares were withheld to cover tax obligations related to equity compensation. These transactions are tax-withholding dispositions, not open-market sales, and Weinberg now holds 244,512 shares of Class A Common Stock directly.
Evolent Health (EVH) CAO awarded PSUs while shares withheld for taxes
Evolent Health's Chief Accounting Officer, Shams Aammaad, was granted 55,173 performance-based share units (PSUs) and 1,686 shares of Class A Common Stock. Simultaneously, various amounts of Class A shares (4,311, 850, and 2,577) were withheld to cover tax obligations from the vesting and settlement of prior awards. The new PSUs are conditional on stock price performance from March 2027 to February 2029, with potential payouts ranging from 0% to 250% of the target level.
Evolent Health Shares Soar on Q4 Earnings and 2026 Revenue Guidance - News and Statistics
Evolent Health's shares surged by over 20% after the company exceeded fourth-quarter earnings expectations and provided a robust revenue forecast for 2026, targeting $2.4 billion to $2.6 billion. This optimistic outlook, suggesting approximately 30% growth, outweighed concerns about lower-than-expected adjusted EBITDA guidance. The stock's volatile performance and a recent gain fueled by hopes for interest rate cuts following a soft inflation report also contributed to market sentiment.
Evolent to Participate in Upcoming Investor Conferences
Evolent Health, Inc. announced its executive management team will participate in two upcoming investor conferences: the Cowen 46th Annual Healthcare Conference in Boston on March 3, 2026, and the Oppenheimer 36th Annual Healthcare MedTech and Services Conference virtually on March 17, 2026. Webcasts and replays of these events will be available on Evolent's investor relations website. The company specializes in improving health outcomes for people with complex conditions.
Evolent Health Q4 Loss Of US$3.84 Per Share Tests Bullish Margin Turnaround Narrative
Evolent Health (EVH) reported a Q4 loss of US$3.84 per share and a full-year 2025 net loss of US$579.4 million, challenging a bullish narrative of margin improvement. While revenue growth is around 15% annually, net losses have worsened faster at 21.2% per year over the last five years. The company's low P/S ratio of 0.2x and a DCF fair value of US$10.51 suggest a potential valuation gap for investors willing to look past its substantial losses.
Analysts Offer Insights on Healthcare Companies: Evolent Health (EVH) and Nanosonics Limited (OtherNNCSF)
Two healthcare companies, Evolent Health (EVH) and Nanosonics Limited (NNCSF), recently received bullish ratings from analysts. William Blair reiterated a Buy rating on Evolent Health with an $8.00 average price target, while Morgans maintained a Buy rating on Nanosonics Limited with an A$4.00 price target. These recommendations highlight positive sentiment in the Healthcare sector for these companies.
Evolent Health Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
Over the last quarter, four analysts have provided varying ratings for Evolent Health (NYSE: EVH), ranging from bullish to bearish. The average 12-month price target for EVH is $8.5, indicating a 26.85% decrease from the previous average. Financial insights reveal Evolent Health has a market capitalization below industry averages, a negative revenue trend with a 22.83% decline, but strong net margin at -5.62%.
Evolent Health, Inc. SEC 10-K Report
Evolent Health, Inc. has released its annual 10-K report, detailing a significant decrease in total revenue to $1,876.2 million and a net loss of $579.4 million, largely due to a goodwill impairment charge. The company focuses on specialty care management and uses proprietary technology to deliver value-based care, despite operating in a complex regulatory environment and facing risks related to reliance on large partners and revenue unpredictability. Strategic initiatives include the sale of Evolent Care Partners and capital management to optimize its financial structure and pursue future growth.
EVH SEC Filings - Evolent Health Inc 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for Evolent Health (EVH) SEC filings, including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms. It details recent financial activities, strategic transactions like the sale of its value-based primary care business, and governance changes, along with AI-powered summaries for quick understanding. The article also provides key financial data such as current stock price, market cap, and insider trading activities.
Evolent To Release 2025 Fourth Quarter and Year-End Financial Results on Tuesday, February 24, 2026
Evolent Health, Inc. (NYSE: EVH) announced it will release its 2025 fourth-quarter and year-end financial results on Tuesday, February 24, 2026, after market close, followed by a conference call at 5 p.m. ET. Shareholders and interested participants can access the live broadcast and an audio playback on Evolent's investor relations website. The company specializes in improving health outcomes for people with complex conditions, focusing on making healthcare simpler and more affordable.
Evolent Health to offer $140M in convertible notes, Targets 2025 debt, stock buyback
Evolent Health announced a private offering of $140 million in convertible senior notes due in 2029, with an option for initial purchasers to buy an additional $21 million. The company expects to use the net proceeds to repay its 2025 convertible notes and potentially repurchase shares of its Class A common stock. Additionally, Evolent Health plans to enter into capped call transactions to mitigate potential dilution from the conversion of the notes.
Evolent Health, Inc. - Class A Shares (EVH) Stock Price Today & Analysis
This article provides an analysis of Evolent Health, Inc. (EVH) stock, including its current price, fundamental financials, and corporate information. It details how to buy EVH stock on the Gotrade app, explains fractional shares, and clarifies that EVH does not currently pay dividends as it is a growth stock. The article also covers market hours, safety information for Gotrade, and methods for evaluating if a stock is expensive or cheap.
Take Care Before Diving Into The Deep End On Evolent Health, Inc. (NYSE:EVH)
Evolent Health, Inc. (NYSE:EVH) has a low price-to-sales (P/S) ratio of 0.2x, significantly below the Healthcare Services industry average. While analysts forecast comparable revenue growth for Evolent Health against the industry, its recent short-term revenue decline may be contributing to the low P/S ratio. Investors are advised to consider potential unobserved threats and revenue volatility despite the subdued risk of a price drop.
Price-Driven Insight from (EVH) for Rule-Based Strategy
This article from Stock Traders Daily provides a price-driven insight for Evolent Health Inc Class A (NYSE: EVH) using AI models. It outlines institutional trading strategies including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis. The platform offers real-time entry and exit signals, risk-reward ratios, and custom risk management settings.
To recruit its new finance chief, Evolent puts $2.35M in stock on the table
Evolent (NYSE: EVH) announced a one-time inducement restricted stock unit award of 587,500 shares, valued at $2.35 million, to its new Chief Financial Officer, Mario Ramos. This award was granted under NYSE Listing Rule 303A.08 because Ramos was not a prior employee and will vest over three years, contingent on his continued employment. The market reacted positively, with EVH shares gaining 1.54% on the day this news was published.
Evolent Reports Inducement Award Under NYSE Listing Rule 303A.08
Evolent Health, Inc. announced a one-time restricted stock unit award of 587,500 shares to Mr. Mario Ramos, their new Chief Financial Officer, effective January 2, 2026. This Inducement Award, valued at $2,350,000, is a material inducement for his employment and vests over three years, contingent on his continued employment. The award was granted in accordance with New York Stock Exchange Listing Rule 303A.08.
Evolent Reports Inducement Award Under NYSE Listing Rule 303A.08
Evolent Health, Inc. announced a one-time inducement award of 587,500 restricted stock units to its new Chief Financial Officer, Mr. Mario Ramos, effective January 2, 2026. This award, valued at $2,350,000, vests over three years and was granted in accordance with NYSE Listing Rule 303A.08, as Mr. Ramos was a new hire. Evolent specializes in health outcomes for complex conditions.
Evolent Reports Inducement Award Under NYSE Listing Rule 303A.08 – Company Announcement
Evolent Health, Inc. announced that its Compensation Committee approved a one-time restricted stock unit award for 587,500 shares to its new Chief Financial Officer, Mario Ramos. This inducement award, valued at $2,350,000, vests over three years and is contingent on his continued employment. The grant complies with NYSE Listing Rule 303A.08, as Mr. Ramos was not previously an Evolent employee.
Evolent Reports Inducement Award Under NYSE Listing Rule 303A.08
Evolent Health, Inc. announced a one-time inducement award of 587,500 restricted stock units to its new Chief Financial Officer, Mr. Mario Ramos, effective January 2, 2026. This award, valued at $2,350,000, vests over three years, contingent on continued employment. The grant complies with NYSE Listing Rule 303A.08, as Mr. Ramos was not a previous employee.
